GlycoMimetics Net Worth
GlycoMimetics Net Worth Breakdown | GLYC |
GlycoMimetics Net Worth Analysis
GlycoMimetics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including GlycoMimetics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of GlycoMimetics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform GlycoMimetics' net worth analysis. One common approach is to calculate GlycoMimetics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares GlycoMimetics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing GlycoMimetics' net worth. This approach calculates the present value of GlycoMimetics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of GlycoMimetics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate GlycoMimetics' net worth. This involves comparing GlycoMimetics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into GlycoMimetics' net worth relative to its peers.
Enterprise Value |
|
To determine if GlycoMimetics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding GlycoMimetics' net worth research are outlined below:
| GlycoMimetics is way too risky over 90 days horizon | |
| GlycoMimetics has some characteristics of a very speculative penny stock | |
| GlycoMimetics appears to be risky and price may revert if volatility continues | |
| GlycoMimetics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (37.88 B) with profit before overhead, payroll, taxes, and interest of 10 K. | |
| GlycoMimetics currently holds about 60.24 M in cash with (31.1 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.15, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| GlycoMimetics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: GlycoMimetics Research Coverage Started at StockNews.com |
GlycoMimetics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in GlycoMimetics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to GlycoMimetics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know GlycoMimetics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as GlycoMimetics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading GlycoMimetics backward and forwards among themselves. GlycoMimetics' institutional investor refers to the entity that pools money to purchase GlycoMimetics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Caxton Corp | 2024-12-31 | 203.6 K | State Street Corp | 2024-12-31 | 179.3 K | Northern Trust Corp | 2024-12-31 | 117 K | Xtx Topco Ltd | 2024-12-31 | 64.2 K | Jane Street Group Llc | 2024-12-31 | 58.9 K | Intellectus Partners, Llc | 2024-12-31 | 46 K | Renaissance Technologies Corp | 2024-12-31 | 41.2 K | Susquehanna International Group, Llp | 2024-12-31 | 40.8 K | Ieq Capital, Llc | 2024-12-31 | 38.4 K | Bvf Inc | 2024-12-31 | 9.5 M | Logos Global Management Lp | 2024-12-31 | 5.4 M |
Follow GlycoMimetics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 17.37 M.Market Cap |
|
Project GlycoMimetics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.94) | (0.98) | |
| Return On Capital Employed | (7.54) | (7.16) | |
| Return On Assets | (0.94) | (0.98) | |
| Return On Equity | (1.10) | (1.16) |
When accessing GlycoMimetics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures GlycoMimetics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of GlycoMimetics' profitability and make more informed investment decisions.
Please note, the presentation of GlycoMimetics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, GlycoMimetics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of GlycoMimetics' management manipulating its earnings.
Evaluate GlycoMimetics' management efficiency
GlycoMimetics has return on total asset (ROA) of (0.7204) % which means that it has lost $0.7204 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7325) %, meaning that it created substantial loss on money invested by shareholders. GlycoMimetics' management efficiency ratios could be used to measure how well GlycoMimetics manages its routine affairs as well as how well it operates its assets and liabilities. As of March 18, 2025, Return On Tangible Assets is expected to decline to -0.98. The current year's Return On Capital Employed is expected to grow to -7.16. At present, GlycoMimetics' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 11.6 B, whereas Non Current Assets Total are forecasted to decline to 0.00.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 82.41 | 86.53 | |
| Tangible Book Value Per Share | 82.41 | 86.53 | |
| Enterprise Value | 72.2 M | 65.9 M |
The strategic vision of GlycoMimetics management plays a critical role in its financial performance. By evaluating this vision, we provide insights into the stock's growth potential.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific GlycoMimetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on GlycoMimetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases GlycoMimetics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
GlycoMimetics time-series forecasting models is one of many GlycoMimetics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary GlycoMimetics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
GlycoMimetics Earnings per Share Projection vs Actual
GlycoMimetics Corporate Executives
Elected by the shareholders, the GlycoMimetics' board of directors comprises two types of representatives: GlycoMimetics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GlycoMimetics. The board's role is to monitor GlycoMimetics' management team and ensure that shareholders' interests are well served. GlycoMimetics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GlycoMimetics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Brian Hahn | CFO and Principal Accounting Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlycoMimetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade GlycoMimetics Stock refer to our How to Trade GlycoMimetics Stock guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlycoMimetics. If investors know GlycoMimetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlycoMimetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of GlycoMimetics is measured differently than its book value, which is the value of GlycoMimetics that is recorded on the company's balance sheet. Investors also form their own opinion of GlycoMimetics' value that differs from its market value or its book value, called intrinsic value, which is GlycoMimetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlycoMimetics' market value can be influenced by many factors that don't directly affect GlycoMimetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlycoMimetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if GlycoMimetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlycoMimetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.